ArticleACS omega2025
Characterization of Synthesized Ramucirumab-vcMMAE as a Potential Therapeutic Approach in Ovarian Cancer.
Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Current chemotherapy for ovarian cancer, often detected at a late stage, causes side effects and drug resistance. This highlights the necessity for targeted drug delivery systems. The study focuses on in vitro testing of Antibody-Drug Conjugate (ADC) for smarter, more selective cancer cell targeting. In the study, the conjugate was synthesized by reducing the interchain disulfide bonds of Ramucirumab, followed by alkylation with mc-vc-PAB-MMAE (vcMMAE). The synthesized conjugate underwent structural, physicochemical, and functional analyses, followed by an assessment of its in vitro efficacy in ovarian cancer cell lines with normal, primary and metastatic characteristics. It was found that Ramucirumab-mc-vc-PAB-MMAE (R-vcMMAE) had a mean drug-to-antibody ratio of 3.2 and a monomeric protein content of over 95%. Moreover, the conjugation process had a low effect on the binding ability of R-vcMMAE to ovarian cancer cells. The results showed that the R-vcMMAE conjugate inhibited 50% of ovarian cancer cell viability at approximately 6 nM without affecting normal ovarian cell viability. In vitro studies indicated that the synthesized ADC exhibited minimal aggregation, did not adversely affect the antibody's binding to the antigen, and displayed efficacy.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.